The End of Days: Predictions & Interpretations
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of patients taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- The SELECT trial focused on individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke,...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What happened? A Closer Look at teh SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated meaningful weight loss,the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
Key Findings: The Numbers Tell the Story
The study found that 6.5% of patients taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. While statistically significant, it’s crucial to understand the absolute risk difference and the specific characteristics of the patients who experienced these events.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 3.7 | 2.6 |
| Non-Fatal Stroke | 2.9 | 2.2 |
| Non-Fatal Heart Attack | 2.5 | 1.9 |
| MACE (Combined) | 6.5 | 4.9 |
Who is Affected? Understanding the Patient Profile
The SELECT trial focused on individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease. This is a critical distinction. The increased risk was observed in this specific subgroup, and the findings do not necessarily apply to individuals using semaglutide for weight loss without pre-existing cardiovascular conditions. Furthermore, the average age of participants was 61, suggesting older adults may be more vulnerable.
It’s crucial to note that the trial excluded patients with type 2 diabetes,meaning the results cannot be directly extrapolated to this population. The impact of semaglutide on cardiovascular outcomes in diabetic patients remains an area of ongoing research.
Why This matters: Beyond Weight Loss
Semaglutide, initially developed for diabetes management, gained widespread popularity for its dramatic weight loss effects. Its potential cardiovascular benefits were previously suggested by trials like LEVO, which showed a reduction in MACE in diabetic patients. The SELECT trial challenges this narrative, highlighting the complexity of the drug’s effects and the importance of considering individual patient risk factors.
Timeline of Events & Ongoing Research
- 2017-2023: SELECT